Zobrazeno 1 - 10 of 20 pro vyhledávání: '"Patricia B. Brown"'
2
Clinical trial conduct in special populations and developing regions: An overview of the DOVE study in pediatric patients with sickle cell disease
Autor: Patricia B. Brown, Linda Messana, Stephen G. Reams, Kevin Nanry, Alexandria E. Gunnell
Publikováno v: Contemporary Clinical Trials. 64:88-94
Clinical trials conducted in unique patient populations or individuals with rare diseases are typically hampered by limitations in availability of qualified patients, requiring sponsors to broaden their global outreach to achieve enrollment. Engaging
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34402009972522edfb6727882edaed48
https://doi.org/10.1016/j.cct.2017.11.003
Zobrazit plný text záznamu
3
Successful utilization of an electronic pain diary in a multinational phase 3 interventional study of pediatric sickle cell anemia
Autor: Nicoletta Masera, Carlton Dampier, Tsiri Agbenyega, Joseph A. Jakubowski, Chunmei Zhou, Lori E. Heath, Carolyn Hoppe, Samuel Adjei, Matthew M. Heeney, Mohamed M. Badr, Patricia B. Brown
Publikováno v: Clinical Trials. 14:563-571
Background/Aims: Patients with sickle cell anemia can experience recurrent pain episodes, which affect quality of life. The reported prevalence of pain is higher in studies using patient diaries than in healthcare facility utilization data. Determini
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0712d3001f0194396a4a1713ee3f4785
https://doi.org/10.1177/1740774517723307
Zobrazit plný text záznamu
4
Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study
Autor: Raffaella Colombatti, Suqin Yao, Hoda Hassab, Miguel R. Abboud, Chunmei Zhou, Baba Inusa, Patricia B. Brown, Joseph A. Jakubowski, Lori E. Heath, Matthew M. Heeney, David C. Rees, Bernhards Ogutu, Carolyn Hoppe
Publikováno v: Journal of Clinical Medicine
Volume 8
Issue 11
Journal of Clinical Medicine, Vol 8, Iss 11, p 2009 (2019)
Background: DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) was a Phase 3, randomized, double-blind, placebo-controlled study conducted in children with sickle cell anemia at 51 sites in 13 countries across four continents.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::103bf88418f9ebb25249da68acaf9480
https://pubmed.ncbi.nlm.nih.gov/31744266
Zobrazit plný text záznamu
5
The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: A retrospective analysis of the FEATHER study
Autor: Brian A. Moser, Kenneth J. Winters, Joseph A. Jakubowski, Stefan James, David Erlinge, Patricia B. Brown, Dominick J. Angiolillo, Chunmei Zhou, David S. Small, Jurriën M. ten Berg
Publikováno v: Thrombosis Research. 134:552-557
Introduction Patients treated with clopidogrel who have higher body size exhibit greater platelet reactivity than patients with lower body size. In a retrospective analysis of the FEATHER trial, we examined the relationship between platelet response
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98437310a8b39eeb513f3c7aee3b1df2
https://doi.org/10.1016/j.thromres.2014.05.019
Zobrazit plný text záznamu
7
Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia
Autor: Carolyn Hoppe, Baba Inusa, Neehar Gupta, Julie Kanter, Chunmei Zhou, Lori E. Heath, Joseph A. Jakubowski, Brendan E. Smith, Patricia B. Brown, David C. Rees, Suqin Yao, Matthew M. Heeney, David S. Small
Publikováno v: Thrombosis and haemostasis. 117(3)
SummaryPatients with sickle cell anaemia (SCA) have vaso-occlusive crises resulting from occlusive hypoxic-ischaemic injury. Prasugrel inhibits platelet activation and aggregation involved in SCA pathophysiology. Determining Effects of Platelet Inhib
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd524dafce82edac8625bee932e63589
https://pubmed.ncbi.nlm.nih.gov/27929203
Zobrazit plný text záznamu
8
Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients
Autor: Catharina Borna, Christian Lood, Lennart Truedsson, Joseph A. Jakubowski, Henrik Wagner, David Erlinge, Patricia B. Brown, Olof Gidlöf, Chunmei Zhou, Kenneth J. Winters
Publikováno v: Journal of thrombosis and thrombolysis. 42(3)
Platelet P-selectin and activated glycoprotein IIb–IIIa (GPIIb–IIIa) are markers of platelet activation and mediates platelet aggregation. Prasugrel (Pras) 5 mg may be used in very elderly (VE) acute coronary syndrome (ACS) patients undergoing PC
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e9121ed02fa67cb4d5c24cc10bc8fd2
https://pubmed.ncbi.nlm.nih.gov/27165280
Zobrazit plný text záznamu
9
A multinational trial of prasugrel for sickle cell vaso-occlusive events
Autor: David C. Rees, Raffaella Colombatti, Miguel R. Abboud, Nancy Robitaille, Hoda Hassab, Catherine I. Segbefia, Chunmei Zhou, Julie Kanter, Tsiri Agbenyega, Patricia B. Brown, Dmitry Zamoryakhin, Videlis Nduba, Janet Oyieko, Bernhards Ogutu, Lori E. Heath, Joseph A. Jakubowski, Matthew M. Heeney, Baba Inusa, Carolyn Hoppe
Publikováno v: Heeney, M M, Hoppe, C C, Abboud, M R, Inusa, B, Kanter, J, Ogutu, B, Brown, P B, Heath, L E, Jakubowski, J A, Zhou, C, Zamoryakhin, D, Agbenyega, T, Colombatti, R, Hassab, H M, Nduba, V N, Oyieko, J N, Robitaille, N & Segbefia, C I & Rees, D C 2016, ' A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events ', New England Journal of Medicine, vol. 374, no. 7, pp. 625-635 . https://doi.org/10.1056/NEJMoa1512021
BACKGROUNDSickle cell anemia is an inherited blood disorder that is characterized by painfulvaso-occlusive crises, for which there are few treatment options. Platelets mediate intercellular adhesion and thrombosis during vaso-occlusion in sickle cell
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84bbb6aa9c565795e55cf15d73bc3734
http://hdl.handle.net/11577/3353240
Zobrazit plný text záznamu
10
Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients
Autor: Henrik Wagner, Jurriën M. ten Berg, Thomas O. Bergmeijer, Chunmei Zhou, Brian A. Moser, Kenneth J. Winters, Stefan James, David Erlinge, Junxiang Luo, Patricia B. Brown, Dominick J. Angiolillo, Joseph A. Jakubowski, David P. Foley, David S. Small
Publikováno v: Journal of the American College of Cardiology. 60:2032-2040
Objectives The aim of this study was to confirm prior modeling data suggesting that prasugrel 5 mg in low-body-weight (LBW) patients would be noninferior to prasugrel 10 mg in higher-body-weight (HBW) patients as assessed by maximal platelet aggregat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::574854a00c9fa17591820a7ffba52adb
https://doi.org/10.1016/j.jacc.2012.08.964
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje